Cronus Pharma Llc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Cronus Pharma Llc Pharmaceutical Import Records from India — 2 Products, $5.5M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Cronus Pharma Llc — Pharmaceutical Importer Profile (2026) | 2 Products, $5.5M Trade | TransData Nexus

Cronus Pharma Llc

Pharmaceutical Importer · United States · Antibiotics Focus · $5.5M Total Trade · DGFT Verified

Cronus Pharma Llc is a pharmaceutical importer based in United States with a total trade value of $5.5M across 2 products in 2 therapeutic categories. Based on 109 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Cronus Pharma Llc sources from 2 verified Indian suppliers, with Aurobindo Pharma Limited accounting for 94.1% of imports.

Cronus Pharma Llc — Import Portfolio & Supplier Network

Cronus Pharma Llc import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Cronus Pharma Llc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Aurobindo Pharma Limited	$4.8M	115	94.1%
Spicejet Limited	$300.0K	6	5.9%

Cronus Pharma Llc sources from 2 verified Indian suppliers across 80 distinct formulations. The sourcing is highly concentrated — Aurobindo Pharma Limited accounts for 94.1% of total imports, indicating a strategic single-source relationship.

What Formulations Does Cronus Pharma Llc Import?

Formulation	Value	Ships
Cephalexin capsules 500MG (cephalexin	$207.2K	7
Cephalexin capsules 250MG (cephalexin capsules USP 250 MG)	$195.5K	6
Cefpodoxime proxetil tablets 200MG	$150.0K	3
Cephalexin capsules 500MG (cephalexin capsules USP 500 MG) (6941 x 500's packs =3470500 nos	$150.0K	3
Cephalexin capsules 500MG (cephalexin capsules USP 500 MG) (6956 x 500's packs =3478000 nos	$150.0K	3
Cefpodoxime proxetil tablets 200MG (cefpodoxime proxetil tablets, USP 200MG) (6706 Pack)	$150.0K	3
Cefpodoxime proxetil tablets 200MG (cefpodoxime proxetil tablets, USP 200MG) (6730 Pack)	$150.0K	3
Cephalexin capsules USP 500MG (5814 x 500's Pack)	$140.5K	3
Cefpodoxime proxetil tablets 200MG ( cefpodoxime proxetil tablets USP 200 MG )	$133.0K	3
Cefpodoxime proxetil tablets USP 200MG (3383 x 100's Pack)	$131.3K	3
Cefpodoxime proxetil tablets 100MG (cefpodoxime proxetil tablets, USP 100MG) (6646 Pack)	$110.8K	3
Cefpodoxime proxetil tablets USP 100MG	$100.0K	2
Cefpodoxime proxetil tablets USP 200 MG	$100.0K	2
Cefpodoxime proxetil tablets USP 200MG	$100.0K	2
Cephalexin capsules 500MG	$100.0K	2

Cronus Pharma Llc imports 80 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Cephalexin	Antibiotics	$3.0M	60	0.4%	11
2	Cefpodoxime	Advanced Antibiotics	$2.5M	49	1.6%	2

Cronus Pharma Llc imports 2 pharmaceutical products across 2 categories into United States totaling $5.5M.

Cronus Pharma Llc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Cronus Pharma LLC is a privately held veterinary pharmaceutical company headquartered in East Brunswick, New Jersey. Established in 2012, the company specializes in the research, development, manufacturing, and marketing of generic veterinary pharmaceuticals. Its product portfolio includes antibiotics, sedatives, analgesics, and preanesthetics, catering to companion, equine, and production animal markets. Cronus Pharma's products are accessible to veterinarians and pet owners nationwide through national and regional distributors.

The company operates as a limited liability company (LLC) and is classified under the North American Industry Classification System (NAICS) code 424210, which pertains to drugs and druggists' sundries merchant wholesalers. Cronus Pharma's mission is to provide cost-effective and innovative veterinary pharmaceutical solutions, aiming to become a leading manufacturer in the U.S. animal health market.

2Distribution Network

Cronus Pharma LLC's distribution network is designed to ensure nationwide accessibility of its veterinary pharmaceutical products. While specific warehouse locations are not publicly disclosed, the company is licensed in all 50 states to distribute pharmaceutical products. This extensive licensing indicates a robust logistics capability, enabling the company to serve a wide geographic area across the United States.

3Industry Role

In the United States pharmaceutical supply chain, Cronus Pharma LLC functions primarily as a wholesaler and distributor of veterinary pharmaceuticals. By sourcing generic veterinary drugs and making them available through national and regional distributors, the company plays a crucial role in ensuring that veterinarians and pet owners have access to cost-effective and quality medications.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Cronus Pharma Llc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Cronus Pharma LLC's sourcing strategy exhibits a high degree of concentration, with a total import value of $5.5 million USD from India across 109 shipments, importing 80 unique formulations. The top two products—Cephalexin and Cefpodoxime—account for 100% of the company's imports from India, indicating a complete reliance on these two products. This sourcing pattern suggests a strategic choice to focus on high-demand antibiotics, but it also presents a risk due to the lack of diversification in the product portfolio.

The shipment data reveals a stable relationship with two Indian suppliers: Aurobindo Pharma Limited, accounting for 94.1% of the shipments, and SpiceJet Limited, accounting for 5.9%. The dominance of Aurobindo Pharma Limited indicates a strong and possibly exclusive partnership, which could be advantageous in terms of pricing and supply chain reliability. However, the limited number of suppliers may expose Cronus Pharma to supply chain disruptions if any issues arise with these partners.

2Supply Chain Resilience

Cronus Pharma LLC's supply chain resilience is closely tied to its sourcing strategy. The company's heavy reliance on a single supplier, Aurobindo Pharma Limited, for the majority of its imports from India, coupled with the focus on only two products, suggests limited diversification. This lack of diversification could pose challenges in maintaining a consistent supply of products, especially if there are disruptions in the manufacturing or shipping processes. Additionally, the company's dependence on a single supplier may limit its ability to negotiate better terms or adapt to changing market conditions.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) is the primary regulatory authority overseeing the importation and distribution of pharmaceutical products, including veterinary drugs. The FDA ensures that imported drugs meet the same standards for quality, safety, and effectiveness as those manufactured domestically. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act, which sets forth requirements for drug approval, labeling, and manufacturing practices. The FDA's Center for Veterinary Medicine (CVM) specifically oversees the approval and regulation of animal drugs.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in the United States are stringent. Companies like Cronus Pharma LLC must ensure that their imported products comply with FDA regulations, including obtaining necessary approvals and adhering to Good Manufacturing Practice (GMP) standards. The FDA recognizes GMP certifications from various international bodies, such as the European Union (EU) GMP, World Health Organization (WHO) GMP, and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications are crucial for ensuring the quality and safety of imported pharmaceutical products.

Quality & Labeling

Cronus Pharma Llc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Cronus Pharma LLC's focus on antibiotics, particularly Cephalexin and Cefpodoxime, aligns with the high demand for effective treatments of bacterial infections in animals. The company's strategy to import these specific therapeutic areas suggests a targeted approach to meet market needs. The dominance of these products in the import portfolio indicates a strategic choice to concentrate resources on high-demand items, potentially leading to economies of scale and stronger supplier relationships.

2Sourcing Profile

Cronus Pharma LLC's sourcing strategy is centered on importing generic veterinary drugs from India, with a particular emphasis on antibiotics. The company's focus on finished pharmaceutical formulations, such as tablets, capsules, syrups, and injections, indicates a preference for ready-to-market products. India's established pharmaceutical manufacturing capabilities and cost advantages make it a suitable source for these products, fitting well into Cronus Pharma's overall procurement strategy.

3Market Positioning

Based on its product mix, Cronus Pharma LLC serves the wholesale distribution segment of the United States market. By importing generic veterinary pharmaceuticals and distributing them through national and regional channels, the company plays a pivotal role in ensuring that veterinarians and pet owners have access to affordable and effective animal health medications.

Seller's Guide — How to Become a Supplier to Cronus Pharma Llc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter Cronus Pharma LLC's supply chain. The company's concentrated sourcing strategy and reliance on a limited number of suppliers suggest potential gaps in its current sourcing. Indian exporters can capitalize on this by offering competitive pricing, reliable supply chains, and high-quality products to diversify Cronus Pharma's supplier base and enhance supply chain resilience.

2Requirements & Qualifications

Indian exporters seeking to supply Cronus Pharma LLC and the U.S. market must ensure that their products comply with FDA regulations, including obtaining necessary approvals and adhering to GMP standards recognized by the FDA. Additionally, products must meet FDA requirements for batch testing, stability, labeling, and serialization. Establishing a strong relationship with Cronus Pharma and demonstrating the ability to meet these standards are crucial steps for Indian exporters.

3How to Approach

Frequently Asked Questions — Cronus Pharma Llc

What products does Cronus Pharma Llc import from India?

Cronus Pharma Llc imports 2 pharmaceutical products across 2 categories. Top imports: Cephalexin ($3.0M), Cefpodoxime ($2.5M).

Who supplies pharmaceuticals to Cronus Pharma Llc from India?

Cronus Pharma Llc sources from 2 verified Indian suppliers. The primary supplier is Aurobindo Pharma Limited (94.1% of imports, $4.8M).

What is Cronus Pharma Llc's total pharmaceutical import value?

Cronus Pharma Llc's total pharmaceutical import value from India is $5.5M, based on 109 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Cronus Pharma Llc focus on?

Cronus Pharma Llc imports across 2 categories. The largest: Antibiotics (55.0%), Advanced Antibiotics (45.0%).

Get Full Cronus Pharma Llc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.